Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. (Q45957722)
Jump to navigation
Jump to search
scientific article published on 23 June 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. |
scientific article published on 23 June 2009 |
Statements
1 reference
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. (English)
1 reference
Cheolwon Suh
1 reference
Byung Woog Kang
1 reference
Won Seog Kim
1 reference
Chul Kim
1 reference
Geundoo Jang
1 reference
Sung Sook Lee
1 reference
Yoon Hee Choi
1 reference
Dae Ho Lee
1 reference
Sang We Kim
1 reference
Shin Kim
1 reference
Jin-Sook Ryu
1 reference
Jooryung Huh
1 reference
Jung Shin Lee
1 reference
23 June 2009
1 reference
1 reference
28
1 reference
4
1 reference
516-522
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference